Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Lasmiditan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1F known ✓ | P30939 | 19/20 | 0.89 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.89 |
| ▸ | DRD5 | P21918 | 1/20 | 0.89 |
| ▸ | HTR1D | P28221 | 1/20 | 0.89 |
| ▸ | HTR1E | P28566 | 1/20 | 0.89 |
| ▸ | HTR7 | P34969 | 1/20 | 0.89 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.89 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.89 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.89 |
| ▸ | HTR1A | P08908 | 1/20 | 0.61 |
| ▸ | HTR1B | P28222 | 1/20 | 0.61 |
| ▸ | HTR2A | P28223 | 1/20 | 0.61 |
| ▸ | HTR2C | P28335 | 1/20 | 0.61 |
| ▸ | HTR2B | P41595 | 1/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lasmiditan SCHEMBL29376817 | 0.94 | HTR1F (1.00) | HTR1FCHRM5DRD5HTR1DHTR1E | |
| Lasmiditan SCHEMBL536057 | 0.94 | HTR1F (1.00) | HTR1FCHRM5DRD5HTR1DHTR1E | |
| Lasmiditan SCHEMBL25337411 | 0.93 | HTR1F (0.94) | HTR1FCHRM5DRD5HTR1DHTR1E | |
| Lasmiditan SCHEMBL2536468 | 0.93 | HTR1F (0.98) | HTR1FCHRM5DRD5HTR1DHTR1E | |
| Lasmiditan SCHEMBL29598155 | 0.93 | HTR1F (0.98) | HTR1FCHRM5DRD5HTR1DHTR1E | |
| SCHEMBL30730002 | 0.87 | HTR1F (0.85) | HTR1FCHRM5DRD5HTR1DHTR1E | |
| SCHEMBL2537137 | 0.87 | HTR1F (0.85) | HTR1FCHRM5DRD5HTR1DHTR1E | |
| SCHEMBL2541484 | 0.86 | HTR1F (0.81) | HTR1FCHRM5DRD5HTR1DHTR1E | |
| SCHEMBL2539164 | 0.85 | HTR1F (0.79) | HTR1FCHRM5DRD5HTR1DHTR1E | |
| SCHEMBL29031450 | 0.83 | HTR1F (0.79) | HTR1FCHRM5DRD5HTR1DHTR1E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 143 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4096662-B1 | PROCESS FOR PREPARATION OF LASMIDITAN | ALIVUS LIFE SCIENCES LTD (IN) | 2026-03-25 | — | — | EP | claimed |
| US-12378217-B2 | Process for the preparation of lasmiditan | ALIVUS LIFE SCIENCES LIMITED (IN) | 2025-08-05 | — | — | US | claimed |
| US-20250228839-A1 | COMPOSITION OF 2,4,6-TRIFLUORO-N-[6-(1-METHYL-PIPERIDIN-4-CARBONYL)-PYRIDIN-2-YL]-BENZAMIDE | COLUCID PHARMACEUTICALS, INC. | 2025-07-17 | — | — | US | claimed |
| CN-114144408-B | Large scale preparation of 2,4, 6-trifluoro-N- [6- (1-methyl-piperidine-4-carbonyl) -pyridin-2-yl ] -benzamide hemisuccinate and process and intermediates for preparing 2,4, 6-trifluoro-N- [6- (1-methyl-piperidine-4-carbonyl) -pyridin-2-yl ] -benzamide acetate | 伊莱利利公司 | 2025-04-15 | — | — | CN | claimed |
| US-12257246-B2 | Composition of 2,4,6-trifluoro-n-[6-(1-methyl-piperidin-4-carbonyl)-pyridin-2-yl[-benzamide | COLUCID PHARMACEUTICALS, INC. (US) | 2025-03-25 | — | — | US | claimed |
| EP-3996713-B1 | PROCESSES AND INTERMEDIATE FOR THE LARGE-SCALE PREPARATION OF 2,4,6-TRIFLUORO-N-[6-(1-METHYL-PIPERIDINE-4-CARBONYL)-PYRIDIN-2-YL]-BENZAMIDE HEMISUCCINATE | LILLY CO ELI (US) | 2024-12-04 | — | — | EP | claimed |
| US-12071423-B2 | Processes and intermediate for the large-scale preparation of 2,4,6-trifluoro-N-[6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-benzamide hemisuccinate, and preparation of 2,4,6-trifluoro-N-[6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-benzamide acetate | ELI LILLY AND COMPANY (US) | 2024-08-27 | — | — | US | claimed |
| US-20240282425-A1 | AUTHENTICATION METHODS AND SYSTEMS FOR DISPENSED PRESCRIPTIONS | LOW GORDON KEITH (US) | 2024-08-22 | — | — | US | claimed |
| EP-4410784-A2 | PROCESSES AND INTERMEDIATE FOR THE LARGE-SCALE PREPARATION OF 2,4,6-TRIFLUORO-N-[6-(1-METHYL-PIPERIDINE-4-CARBONYL)-PYRIDIN-2-YL]-BENZAMIDE HEMISUCCINATE | Eli Lilly and Company (US) | 2024-08-07 | — | — | EP | claimed |
| US-20240216356-A1 | TASTE MASKED COMPOSTIONS OF 2,4,6-TRIFLUORO-N-[6-(1-METHYL-PIPERIDINE-4-CARBONYL)-PYRIDIN-2-YL]-BENZAMIDE HEMISUCCINATE, AND ORALLY DISENTEGRATING TABLET COMPRISING THE SAME | LILLY CO ELI (US) | 2024-07-04 | — | — | US | claimed |
| US-20230250076-A1 | PROCESSES AND INTERMEDIATE FOR THE LARGE-SCALE PREPARATION OF 2,4,6-TRIFLUORO-N-[6-(1-METHYL-PIPERIDINE-4-CARBONYL)-PYRIDIN-2-YL]-BENZAMIDE HEMISUCCINATE, AND PREPARATION OF 2,4,6-TRIFLUORO-N-[6-(1-METHYL-PIPERIDINE-4-CARBONYL)-PYRIDIN-2-YL]-BENZAMIDE ACETATE | ELI LILLY AND COMPANY | 2023-08-10 | — | — | US | claimed |
| US-20230137090-A1 | PROCESSES AND INTERMEDIATE FOR THE LARGE-SCALE PREPARATION OF 2,4,6-TRIFLUORO-N-[6-(1-METHYL-PIPERIDINE-4-CARBONYL)-PYRIDIN-2-YL]-BENZAMIDE HEMISUCCINATE, AND PREPARATION OF 2,4,6-TRIFLUORO-N-[6-(1-METHYL-PIPERIDINE-4-CARBONYL)-PYRIDIN-2-YL]-BENZAMIDE ACETATE | ELI LILLY AND COMPANY | 2023-05-04 | — | — | US | claimed |
| US-20230095474-A1 | PROCESS FOR THE PREPARATION OF LASMIDITAN | ALIVUS LIFE SCIENCES LIMITED (IN) | 2023-03-30 | — | — | US | claimed |
| EP-4096662-A1 | PROCESS FOR PREPARATION OF LASMIDITAN | Glenmark Life Sciences Limited (IN) | 2022-12-07 | — | — | EP | claimed |
| CN-115385893-A | With pyridine acyl piperidine 5-HT 1F Compositions and methods relating to agonists | 科鲁西德制药公司 | 2022-11-25 | — | — | CN | claimed |
| CN-115385894-A | With pyridine acyl piperidine 5-HT 1F Compositions and methods relating to agonists | 科鲁西德制药公司 | 2022-11-25 | — | — | CN | claimed |
| WO-2022236004-A1 | TASTE MASKED COMPOSTIONS OF 2,4,6-TRIFLUORO- N-[6-(1-METHYL-PIPERIDINE-4-CARBONYL)-PYRIDIN-2- YLJ-BENZAMIDE HEMISUCCINATE, AND ORALLY DISENTEGRATING TABLET COMPRISING THE SAME | ELI LILLY AND COMPANY (US) | 2022-11-10 | — | — | WO | claimed |
| EP-3996713-A1 | PROCESSES AND INTERMEDIATE FOR THE LARGE-SCALE PREPARATION OF 2,4,6-TRIFLUORO-N-[6-(1-METHYL-PIPERIDINE-4-CARBONYL)-PYRIDIN-2-YL]-BENZAMIDE HEMISUCCINATE, AND PREPARATION OF 2,4,6-TRIFLUORO-N-[6-(1-METHYL-PIPERIDINE-4-CARBONYL)-PYRIDIN-2-YL]-BENZAMIDE ACETATE | ELI LILLY AND COMPANY (US) | 2022-05-18 | — | — | EP | claimed |
| CN-114144408-A | Process and intermediates for large scale preparation of 2,4, 6-trifluoro-N- [6- (1-methyl-piperidine-4-carbonyl) -pyridin-2-yl ] -benzamide hemisuccinate and preparation of 2,4, 6-trifluoro-N- [6- (1-methyl-piperidine-4-carbonyl) -pyridin-2-yl ] -benzamide acetate | 伊莱利利公司 | 2022-03-04 | — | — | CN | claimed |
| EP-3551617-B1 | COMPOSITIONS AND METHODS RELATED TO PYRIDINOYLPIPERIDINE 5-HT1F AGONISTS | COLUCID PHARMACEUTICALS INC (US) | 2021-08-11 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240216356-A1 | TASTE MASKED COMPOSTIONS OF 2,4,6-TRIFLUORO-N-[6-(1-METHYL-PIPERIDINE-4-CARBONYL)-PYRIDIN-2-YL]-BENZAMIDE HEMISUCCINATE, AND ORALLY DISENTEGRATING TABLET COMPRISING THE SAME | TAS2R40, TAS2R10, TAS2R13 | HTR1F 88/4885CHRM5 581/4885DRD5 1380/4885 |
| US-12257246-B2 | Composition of 2,4,6-trifluoro-n-[6-(1-methyl-piperidin-4-carbonyl)-pyridin-2-yl[-benzamide | PDGFRA, SLCO1A2, SLCO2A1 | HTR1F 232/4885CHRM5 617/4885DRD5 2390/4885 |
| US-12378217-B2 | Process for the preparation of lasmiditan | LPXN, TACR2, KCNH1 | HTR1F 1498/4885CHRM5 316/4885DRD5 1929/4885 |
| US-12071423-B2 | Processes and intermediate for the large-scale preparation of 2,4,6-trifluoro-N-[6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-benzamide hemisuccinate, and preparation of 2,4,6-trifluoro-N-[6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-benzamide acetate | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, KDM5B, KDM4D | HTR1F 203/4885CHRM5 229/4885DRD5 1811/4885 |
| US-20230137090-A1 | PROCESSES AND INTERMEDIATE FOR THE LARGE-SCALE PREPARATION OF 2,4,6-TRIFLUORO-N-[6-(1-METHYL-PIPERIDINE-4-CARBONYL)-PYRIDIN-2-YL]-BENZAMIDE HEMISUCCINATE, AND PREPARATION OF 2,4,6-TRIFLUORO-N-[6-(1-METHYL-PIPERIDINE-4-CARBONYL)-PYRIDIN-2-YL]-BENZAMIDE ACETATE | LPXN, KDM2A, HTR2A | HTR1F 201/4885CHRM5 391/4885DRD5 2545/4885 |
| US-20250228839-A1 | COMPOSITION OF 2,4,6-TRIFLUORO-N-[6-(1-METHYL-PIPERIDIN-4-CARBONYL)-PYRIDIN-2-YL]-BENZAMIDE | PDGFRA, SLCO1A2, SLCO2A1 | HTR1F 193/4885CHRM5 607/4885DRD5 2313/4885 |
| US-20230095474-A1 | PROCESS FOR THE PREPARATION OF LASMIDITAN | LPXN, TACR2, KCNH1 | HTR1F 1498/4885CHRM5 316/4885DRD5 1929/4885 |
| US-20230250076-A1 | PROCESSES AND INTERMEDIATE FOR THE LARGE-SCALE PREPARATION OF 2,4,6-TRIFLUORO-N-[6-(1-METHYL-PIPERIDINE-4-CARBONYL)-PYRIDIN-2-YL]-BENZAMIDE HEMISUCCINATE, AND PREPARATION OF 2,4,6-TRIFLUORO-N-[6-(1-METHYL-PIPERIDINE-4-CARBONYL)-PYRIDIN-2-YL]-BENZAMIDE ACETATE | LPXN, KDM2A, PMP22 | HTR1F 275/4885CHRM5 304/4885DRD5 2716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.